EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Conditioning Regimen with Bone Marrow Transplant

First Posted Date: 2012-03-28

Last Posted Date: 2017-11-21

Lead Sponsor: Emory University

Target Recruit Count: 22

Registration Number: NCT01565616

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Oakland, Oakland, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 5 locations

Analysis of Percutaneous Ablations for Cancer Treatment

Completed

Conditions: Cancer

First Posted Date: 2012-03-27

Last Posted Date: 2014-05-28

Lead Sponsor: Emory University

Target Recruit Count: 26

Registration Number: NCT01563679

Locations: 🇺🇸
Emory University Hospital, Altanta, Georgia, United States

TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis

Not Applicable

Completed

Conditions: Liver Cancer
Portal Vein Thrombosis

Interventions: Device: TheraSphere

First Posted Date: 2012-03-16

Last Posted Date: 2014-05-28

Lead Sponsor: Emory University

Target Recruit Count: 35

Registration Number: NCT01556282

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer

Phase 1

Completed

Conditions: Rectal Cancer

Interventions: Drug: capecitabine + ganetespib

First Posted Date: 2012-03-15

Last Posted Date: 2016-02-22

Lead Sponsor: Emory University

Target Recruit Count: 16

Registration Number: NCT01554969

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Project N-Liten- HIV Prevention for African American Women

Not Applicable

Completed

Conditions: Sexually Transmitted Diseases

Interventions: Behavioral: Horizons+General Health Promotion (GHP)
Behavioral: Horizons+Motivational Enhancement Therapy (GMET)

First Posted Date: 2012-03-14

Last Posted Date: 2015-06-25

Lead Sponsor: Emory University

Target Recruit Count: 560

Registration Number: NCT01553682

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Panobinostat
Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2012-03-09

Last Posted Date: 2019-01-16

Lead Sponsor: Emory University

Target Recruit Count: 32

Registration Number: NCT01549431

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Phase 2

Terminated

Conditions: Epilepsy, Cryptogenic
Epilepsy, Partial
Limbic Encephalitis
Seizure Disorder
Autoimmune Diseases, Nervous System

Interventions: Drug: IVIG

First Posted Date: 2012-03-06

Last Posted Date: 2014-09-01

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT01545518

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
The Emory Clinic, Inc., Atlanta, Georgia, United States

Effect of Probiotic Supplementation on Immune Function in Healthy Infants

Not Applicable

Completed

Conditions: Inflammation

Interventions: Other: Placebo
Dietary Supplement: Lactobacillus reuteri DSM 17938

First Posted Date: 2012-03-02

Last Posted Date: 2015-03-06

Lead Sponsor: Emory University

Target Recruit Count: 15

Registration Number: NCT01542320

Locations: 🇺🇸
Emory Children's Center, Atlanta, Georgia, United States

Prospective Liver Study

Completed

Conditions: Liver Cancer

First Posted Date: 2012-02-28

Last Posted Date: 2014-05-28

Lead Sponsor: Emory University

Target Recruit Count: 400

Registration Number: NCT01539993

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

Study of Axitinib and Temsirolimus in Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Temsirolimus
Drug: Axitinib

First Posted Date: 2012-02-08

Last Posted Date: 2015-04-13

Lead Sponsor: Emory University

Target Recruit Count: 13

Registration Number: NCT01529138

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy